TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01753167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCMV3068A
Description: Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCMV5322A
Description: Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Study: NCT04191850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Port Video-Assisted Thoracoscopic Surgery
Description: Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Port Video-Assisted Thoracoscopic Surgery
Description: Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
Study: NCT00950365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02909920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Initial Videoconference following telerehabilitation programs self-workout exercise with video support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy
Description: Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
Study: NCT01774838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 3 months treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 3 months treatment
Study: NCT02839590

Intervention type: DEVICE
Intervention: HiFU
Description: Ciliary Ablation Treatment ( HiFu ultrasound treatment)

Intervention type: DEVICE
Intervention: Baerveldt implant
Description: External (sub-conjunctival) Drainage Surgery (Baerveldt implant)

Intervention type: DEVICE
Intervention: Ahmed implant
Description: External (sub-conjunctival) Drainage Surgery (Ahmed Implant)

Intervention type: DEVICE
Intervention: STARflo
Description: Suprachoroidal Shunt Surgery (STARflo)

Intervention type: DEVICE
Intervention: Hydrus Microstent implant
Description: Trans-trabecular meshwork implants (Hydrus Microstent implant).

Intervention type: DEVICE
Intervention: iStent implant
Description: Trans-trabecular meshwork implants (iStent implant).

Intervention type: DEVICE
Intervention: Kahook Dual Blade
Description: It removes part of the trabecular meshwork
Study: NCT01636401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aclidinium bromide 400 μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aclidinium bromide placebo
Study: NCT03703765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lower limb volume estimation
Description: The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort.
Study: NCT02730455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT03306680

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will be assigned to treatment doses using the TITE-CRM model.
Study: NCT03235076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
Study: NCT03584711

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFOX + panitumumab
Description: FOLFOX + panitumumab according to a stop and go strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment
Study: NCT00840294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Study: NCT04464915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol swab
Description: Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
Study: NCT00950365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02668133

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: the nutritional supplement to be used in this trial is a SQ-LNS
Description: Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lipid-based nutrient supplement (SQ-LNS) with phytase
Description: • Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing
Study: NCT03877354

Intervention type: OTHER
Intervention: Data from anaesthesia records for ventilation setting screening
Description: Data from anaesthesia records will be retrospectively screened for the ventilation settings
Study: NCT02668133

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc
Description: delivered orally in sugar solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc
Description: delivered orally in sugar solution

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg isotopically enriched 68Zn
Description: administered intravenously

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 mg isotopically enriched 68Zn
Description: administered intravenously
Study: NCT03877354

Intervention type: OTHER
Intervention: Data from intensive care records for ventilation setting screening
Description: Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
Study: NCT02645214

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-antiseptic scrubs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiseptic scrubs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiseptic scrubs
Study: NCT01512082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field devices
Description: Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
Study: NCT04081051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)
Description: Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
Study: NCT01220596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and Pegylated interferon α-2a Sequential Treatment Group
Description: Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon α-2a Monotreatment Group
Description: Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
Study: NCT00950365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT01512082

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsed electromagnetic field devices
Description: Every persons received two sham pulsed electromagnetic field devices.
Study: NCT03235154

Intervention type: DRUG
Group type: OTHER
Intervention: sofosbuvir/velpatasvir
Description: 12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
Study: NCT01922089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 50 mg/100 mg/200 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 50 mg/100 mg/200 mg bid
Study: NCT00645073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: Two 300 mg cefdinir capsules on Study Days 1-10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: Two 250 mg levofloxacin capsules on Study Days 1-10
Study: NCT00950365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT00229970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 7 mg or 14 mg single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 7 mg or 14 mg single injection
Study: NCT04542824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin
Description: 28-day cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab (maintenance)
Description: 28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab and lenalidomide
Description: 28-day cycles.
Study: NCT03304054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: tablets matching amifampridine phosphate, 3 to 4 times a day
Study: NCT02072135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Study: NCT02172495

Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Tiotropium bromide 18 micrograms
Study: NCT03216304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg safinamide
Description: Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin calcium period 1
Description: Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin calcium period 2
Description: - Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
Study: NCT04636151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary intervention
Description: Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary intervention
Description: Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary intervention
Description: Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
Study: NCT04449874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6036
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6036
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6036
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6036
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6036
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6036
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6036
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
Study: NCT03661983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
Study: NCT01800864

Intervention type: OTHER
Group type: OTHER
Intervention: obesity

Intervention type: OTHER
Group type: OTHER
Intervention: obesity
Study: NCT01953055

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Study: NCT03716882

Intervention type: DEVICE
Intervention: Song Meter (SM)4
Description: Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
Study: NCT03735433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 162mg aspirin dose
Description: 2 pills of 81mg aspirin
Study: NCT04226378

Intervention type: DEVICE
Intervention: Omnipod
Description: Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.

Intervention type: OTHER
Intervention: MDI
Description: Continued use of MDI therapy (traditional basal/bolus insulin regimen).
Study: NCT01979484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 tablet
Study: NCT03655197

Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
Study: NCT00611286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel treatment after bare metal stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel treatment after bare metal stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel after zotarolimus-eluting stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel after paclitaxel-eluting stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel after everolimus-eluting stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel after zotarolimus-eluting stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel after paclitaxel-eluting stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel after everolimus-eluting stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
Study: NCT00438087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone administrated intra and post operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: methylprednisolone administrated intra and post operatively
Study: NCT02315170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraocular injection guide
Description: The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard lid speculum
Description: standard wire lid speculum
Study: NCT00820157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Surgery
Description: Cytoreductive Surgery followed by TACE for MNHCC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE alone or TACE followed by downstage resection for MNHCC
Study: NCT04427774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib plus Sintilimab
Description: Surufatinib will be given orally. Sintilimab will be given intravenously
Study: NCT02716064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAP-CM Intervention
Description: The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
Study: NCT04455802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine or Placebo
Description: The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine or Placebo
Description: The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine or Placebo
Description: If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine or Placebo
Description: If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
Study: NCT02196558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011